Corbion stock holds focus as revenue and EBITDA guide the story

Corbion (NL0010583399) stock is framed by its latest published operating metrics: revenue of EUR 1.33 billion in 2025, adjusted EBITDA of EUR 193.2 million in 2025, and an adjusted EBITDA margin of 14.5% in 2025. Those numbers give investors the clearest snapshot of the Dutch ingredients and biochemicals group’s earnings power, even before a new market quote is added.

EUR 1.33 billion revenue

Corbion reported EUR 1.33 billion in revenue for 2025, while adjusted EBITDA reached EUR 193.2 million and the adjusted EBITDA margin came in at 14.5% in 2025. The comparison that matters is the margin structure: a double-digit EBITDA margin shows the company still converts a meaningful part of sales into operating profit.

That mix matters for valuation because Corbion is not just a volume story. The 2025 numbers show a business with scale, but also one that remains sensitive to margins, input costs, and product mix across food, biobased and preservation applications.

Margin at 14.5%

The 14.5% adjusted EBITDA margin in 2025 is the key bridge between revenue and earnings quality. With EUR 193.2 million of adjusted EBITDA on EUR 1.33 billion of sales, the company’s earnings profile can be read directly from the published figures.

For investors, the comparison is straightforward: revenue is the top line, but margin is the lever that explains how much of that top line turns into cash generation. In a business like Corbion, the margin trend often matters as much as sales growth itself.

Biochemicals remain central

Corbion’s business remains centered on food, preservation, and biobased ingredients, with the company positioned around applications that support shelf life, texture, and industrial uses. That product mix matters because it links revenue quality to recurring demand rather than one-off sales spikes.

The stock case therefore rests less on a single product and more on whether Corbion can sustain its 2025 sales scale while protecting the 14.5% adjusted EBITDA margin. The published figures suggest that margin discipline is the main operating variable.

Price line pending

Corbion shares are listed in Amsterdam, and the latest evidenced company figures provide the valuation backdrop in the absence of a fresh quoted market level in the available source set. The most recent hard numbers in the record remain the 2025 revenue of EUR 1.33 billion, adjusted EBITDA of EUR 193.2 million, and the 14.5% margin.

That leaves the stock story anchored by operating performance rather than a single headline move. The company name, the ISIN, and the annual metrics still give a clear reference point for the market view.

Company details

• Company: Corbion N.V.
• ISIN: NL0010583399
• Ticker: AMS: CRBN
• Trading venue: Euronext Amsterdam
• Sector / Industry: Materials / Specialty Chemicals